海王英特龍2019年第一季度報告聯(lián)合創(chuàng)作 · 2019-05-15 17:19深圳市海王英特龍生物技術(shù)股份有限公司年報瀏覽1點贊 評論 收藏 分享 手機掃一掃分享分享 舉報 評論圖片表情視頻評價全部評論推薦 海王英特龍2019年第三季度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”) GEM has been positioned as a market designed to accommodate s海王英特龍2022年第一季度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”) GEM has been positioned as a market designed to accommodate s海王英特龍2021年第一季度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”) GEM has been positioned as a market designed to accommodate s海王英特龍2023年第一季度報告 2023 First Q%5Cuarterly Report 第一季度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”) GEM has been positioned as海王英特龍2020年第一季度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”) GEM has been positioned as a market designed to accommodate s海王英特龍二零一四年第一季度報告 （於中華人民共和國註冊成立之股份有限公司） 股份代號 （於中華人民共和國註冊成立之股份有限公司） 2014 First Q%5Cuarterly Report 2014 第一季度業(yè)績報告 * 僅供識別之用 * For identification p%5Curpose only 香港聯(lián)合交易所有限公司（「聯(lián)交所海王英特龍海王英特龍秉持「健康成就未來」的理念，以現(xiàn)代生物技術(shù)與藥物制劑技術(shù)為創(chuàng)新平臺，發(fā)展細胞因子類蛋白質(zhì)治療藥物和預(yù)防用生物制品，創(chuàng)建以自主知識產(chǎn)權(quán)產(chǎn)品研發(fā)和專業(yè)化營銷能力為代表的核心競爭力，逐步確立國內(nèi)市海王英特龍海王英特龍秉持「健康成就未來」的理念，以現(xiàn)代生物技術(shù)與藥物制劑技術(shù)為創(chuàng)新平臺，發(fā)展細胞因子類蛋白質(zhì)治海王英特龍2022年第三季度報告 Third Q%5Cuarterly Report 2022第三季度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”) GEM has been positioned as 海王英特龍2020年第三季度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”) GEM has been positioned as a market designed to accommodate s點贊 評論 收藏 分享 手機掃一掃分享分享 舉報
下載APP